ASH 2022 | SKylaRk: Phase II study of Isa-KRD in newly diagnosed, transplant-eligible multiple myeloma
Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, discusses findings from a Phase II trial evaluating the efficacy of a combined regime of carfilzomib, lenalidomide, dexamethasone, and isatuximab (Isa-KRD) in transplant-eligible patients with newly diagnosed multiple myeloma (NCT04430894). So far, early data has shown an overall high response rate to this quadruplet regime as well as a high proportion of patients achieving measurable residual disease (MRD) negativity. Dr Raje also mentions that most patients decided to continue maintenance therapy over receiving stem cell transplantation. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Bristol Myers Squibb: Consultancy, Honoraria; Research to Practice: Honoraria; Medscape: Honoraria; Amgen: Consultancy, Honoraria; Two Seventy Bio: Research Funding; Massachusetts General Hospital: Current Employment; Celgene: Honoraria; Janssen: Consultancy, Honoraria.
